Full Text View
Tabular View
No Study Results Posted
Related Studies
Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-Aminopyridine
This study has been completed.
Study NCT00056810   Information provided by FDA Office of Orphan Products Development
First Received: March 24, 2003   Last Updated: May 18, 2006   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Guillain-Barre Syndrome
Additional conditions recognized in this trial
Syndrome
More general conditions related to this trial
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Diseases
Disease
Immune System Diseases
Nervous System Diseases
Neuromuscular Diseases
Pathologic Processes
Peripheral Nervous System Diseases
Polyneuropathies
Polyradiculoneuropathy
Interventions listed in this trial
4-aminopyridine (4-AP)
Additional drug interventions recognized in this trial
4-Aminopyridine
More general drug interventions related to this trial
Cardiovascular Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Potassium Channel Blockers
Therapeutic Uses
Sponsors listed in this trial
FDA Office of Orphan Products Development


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services